The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 336:1769-1776 June 19, 1997 Number 25
NextNext

Postmenopausal Hormone Therapy and Mortality
Francine Grodstein, Sc.D., Meir J. Stampfer, M.D., Graham A. Colditz, M.B., B.S., Walter C. Willett, M.D., JoAnn E. Manson, M.D., Marshall Joffe, M.D., Bernard Rosner, M.D., Charles Fuchs, M.D., Susan E. Hankinson, Sc.D., David J. Hunter, M.B., B.S., Charles H. Hennekens, M.D., and Frank E. Speizer, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Postmenopausal hormone therapy has both benefits and hazards, including decreased risks of osteoporosis and cardiovascular disease and an increased risk of breast cancer.

Methods We examined the relation between the use of postmenopausal hormones and mortality among participants in the Nurses' Health Study, who were 30 to 55 years of age at base line in 1976. Data were collected by biennial questionnaires beginning in 1976 and continuing through 1992. We documented 3637 deaths from 1976 to 1994. Each participant who died was matched with 10 controls alive at the time of her death. For each death, we defined the subject's hormone status according to the last biennial questionnaire before her death or before the diagnosis of the fatal disease; this reduced bias caused by the discontinuation of hormone use between the time of diagnosis of a potentially fatal disease and death.

Results After adjustment for confounding variables, current hormone users had a lower risk of death (relative risk, 0.63; 95 percent confidence interval, 0.56 to 0.70) than subjects who had never taken hormones; however, the apparent benefit decreased with long-term use (relative risk, 0.80; 0.67 to 0.96, after 10 or more years) because of an increase in mortality from breast cancer among long-term hormone users. Current hormone users with coronary risk factors (69 percent of the women) had the largest reduction in mortality (relative risk, 0.51; 95 percent confidence interval, 0.45 to 0.57), with substantially less benefit for those at low risk (13 percent of the women; relative risk, 0.89; 95 percent confidence interval, 0.62 to 1.28).

Conclusions On average, mortality among women who use postmenopausal hormones is lower than among nonusers; however, the survival benefit diminishes with longer duration of use and is lower for women at low risk for coronary disease.


Source Information

From Channing Laboratory (F.G., M.J.S., G.A.C., W.C.W., J.E.M., B.R., C.F., S.E.H., D.J.H., F.E.S.) and the Division of Preventive Medicine (J.E.M., C.H.H.), the Departments of Medicine and of Ambulatory Care and Prevention (C.H.H.), Brigham and Women's Hospital and Harvard Medical School; and the Departments of Epidemiology (F.G., M.J.S., G.A.C., W.C.W., J.E.M., S.E.H., D.J.H., C.H.H.), Nutrition (M.J.S., W.C.W.), and Biostatistics (M.J., B.R.), Harvard School of Public Health — all in Boston.

Address reprint requests to Dr. Grodstein, Channing Laboratory, 181 Longwood Ave., Boston, MA 02115.

Full Text of this Article


Related Letters:

Postmenopausal Hormone Therapy and Mortality
Whooley M. A., Grady D., Cummings S. R., Green J., Wintfeld N., Atkins C. D., Grodstein F., Stampfer M. J., Willett W. C.
Extract | Full Text  
N Engl J Med 1997; 337:1389-1391, Nov 6, 1997. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.